肺癌实验室诊断专家共识

doi:10.6040/j.issn.1671-7554.0.2018.1020

摘要/Abstract

关键词: 肺癌, 实验室诊断, 肿瘤标志物, 分子标志物, 专家共识

Key words: Lung cancer, Laboratory diagnosis, Tumor marker, Molecular marker, Expert consensus

中图分类号:

R734.2

中国医师协会检验医师分会肺癌检验医学专家委员会. 肺癌实验室诊断专家共识[J]. 山东大学学报 (医学版), 2018, 56(10): 9-17.

[1] 支修益,石远凯,于金明.中国原发性肺癌诊疗规范(2015版)[J].中华肿瘤杂志,2015,37(1): 67-78.
[2] Ando S, Suzuki M, Yamamoto N, et al. The prognostic value of both neuron-specific enolase(NSE)and Cyfra21-1 in small cell lung cancer [J]. Anticancer Res, 2004, 24(3b): 1941-1946.
[3] Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guideline: update 2003[J]. J Clin Oncol, 2004, 22(2): 330-353.
[4] Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer [J]. Oncology, 2001, 61(S1): 3-13.
[5] Petra S, Rudolf H, Stefan H, et al. National Academy of Clinical Biochemistry Guidelines for the Use of Tumor Markers in Lung Cancer[J]. Tumor Biology, 2006.
[6] 中华医学会检验分会,卫生部临床检验中心,中华检验医学杂志编辑委员会. 肿瘤标志物的临床应用建议[J].中华检验医学杂志, 2012, 35(2): 103-116.
[7] 王兰兰,许化溪.临床免疫学检验[M].5版.北京:人民卫生出版社,2013.
[8] Paone G, De Angelis G, Munno R, et al. Discriminant analysis on small-cell lung cancer and non-small-cell lung cancer by means of NSE and CYFRA 21-1[J]. Eur Respir J,1995, 8(7): 1136-1140.
[9] Ebert W, Muley T. CYFRA 21-1 in the follow-up of inoperable non-small-cell lung cancer patients treated with chemotherapy[J]. Anticancer Res, 1999, 19(4A): 2669-2672.
[10] Takei Y, Minato K, Tsuchiya S, et al. CYFRA21-1: an indicator of survival and therapeutic effect in lung cancer[J]. Oncology, 1997, 54(1): 43-47.
[11] 中国合格评定国家认可委员会. CNAS-CL02:2012 医学实验室质量和能力认可准则[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/jbzz/2013/12/750592.shtml, 2013-12-11/2018-09-03.
[12] 中国合格评定国家认可委员会. CNAS-CL38:2012 医学实验室质量和能力认可准则在临床化学检验领域的应用说明[EB/OL]. https://www.cnas.org.cn/rkgf/sysrk/rkyyzz/2014/05/782592.shtml, 2014-05-06/2018-09-03.
[13] 李金明,刘辉.临床免疫学检验技术[M].北京:人民卫生出版社,2015.
[14] 唐古生,沈茜.临床免疫检测的干扰因素和解决办法[A].中华医学会,中华医学会第七次全国中青年检验医学学术会议论文汇编[C] , 2012: 33-34.
[15] 中国医师协会肿瘤医师分会,中国抗癌协会肿瘤临床化疗专业委员会.中国表皮生长因子受体基因敏感性突变和间变淋巴瘤激酶融合基因阳性非小细胞肺癌诊断治疗指南(2015版)[J]. 中华肿瘤杂志, 2015, 37(10): 796-799.
[16] 中华人民共和国国家卫生和计划生育委员会. 药物代谢酶和药物作用靶点基因检测技术指南(试行)和肿瘤个体化治疗检测技术指南(试行)[EB/OL]. 国卫医医护便函〔2015〕240号,http://www.moh.gov.cn/yzygj/s3593/201507/fca7d0216fed429cac797cdafa2ba466.shtml, 2015-07-31/2018-09-03.
[17] 中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家组.中国非小细胞肺癌患者表皮生长因子受体基因突变检测专家共识(2016版)[J].中华病理学杂志, 2016, 45(4): 217-220.
[18] 中国专家共识专家组.非小细胞肺癌血液EGFR基因突变检测中国专家共识[J].中华医学杂志, 2015, 95(46): 3721-3726.
[19] Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology[J]. Arch Pathol Lab Med, 2013, 137(6): 828-860.
[20] Thomas A, Liu SV, Subramaniam DS, et al. Refining the treatment of NSCLC according to histological and molecular subtypes[J]. Nat Rev Clin Oncol, 2015, 12(9): 511-526.
[21] Cheng L, Alexander RE, Maclennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine[J]. Mod Pathol, 2012, 25(3): 347-369.
[22] Piotrowska Z, Sequist LV. Epidermal growth factor receptor-mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options[J]. Cancer J, 2015, 21(5): 371-377.
[23] Zhang K, Yuan Q. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer[J]. J Cancer Res Ther, 2016, 12(Supplement): C131-C137.
[24] Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance[J]. Cancer Discov, 2017, 7(2): 137-155.
[25] Zhang J, Park D, Shin DM, et al. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities[J]. Acta Biochim Biophys Sin(Shanghai), 2016, 48(1): 11-16.
[26] 王恩华,朱明华,步宏,等.非小细胞肺癌靶向药物治疗相关基因检测的规范建议[J].中华病理学杂志, 2016, 45(2): 73-77.
[27] Zhang S, Xia B, Jiang H, et al. Comprehensive profiling and quantitation of oncogenic mutations in non small-cell lung carcinoma using single molecule amplification and re-sequencing technology[J]. Oncotarget, 2016, 7(31): 50477-50489.
[28] Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance[J]. Cancer Med, 2017, 6(1): 154-162.
[29] Malapelle U, Pisapia P, Rocco D, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients[J]. Transl Lung Cancer Res, 2016, 5(5): 505-510.
[30] Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA[J]. Nat Rev Cancer, 2017, 17(4): 223-238.
[31] Normanno N, Denis MG, Thress KS, et al. Guide to detecting epidermal growth factor receptor(EGFR)mutations in ctDNA of patients with advanced non-small-cell lung cancer[J]. Oncotarget, 2017, 8(7): 12501-12516.

相关文章 15

[1]	黄佩文, 王旭东. 治疗非小细胞肺癌新药:靶向c-Met蛋白的抗体药物偶联物Telisotuzumab Vedotin[J]. 山东大学学报 (医学版), 2026, 64(3): 124-130.
[2]	中国医师协会骨科医师分会智能骨科学组,中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组. 人工智能脊柱退变影像学测量位点与标注专家共识(2025)[J]. 山东大学学报 (医学版), 2026, 64(2): 1-10.
[3]	机器人辅助经椎间孔腰椎椎体间融合术手术技术专家组. 机器人辅助经椎间孔腰椎椎体间融合术专家共识[J]. 山东大学学报 (医学版), 2026, 64(2): 11-21.
[4]	祝永才,谢艳,齐秋晨,李培龙,王传新,杜鲁涛. 基于外周血单个核细胞ATM基因甲基化的联合模型在胰腺癌早期诊断中的价值[J]. 山东大学学报 (医学版), 2025, 63(6): 78-88.
[5]	赵汉卿,周新睿,李子建,唐兴. 循环肿瘤细胞联合血清学检测在非小细胞肺癌中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 79-85.
[6]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[7]	徐年兴,魏东,乔俊杰,战炳炎. CD8⁺、IL-6和PaO₂对不可切除Ⅲ_B/C和Ⅳ期非小细胞肺癌免疫治疗触发放射召回性肺炎的预测价值[J]. 山东大学学报 (医学版), 2025, 63(2): 29-35.
[8]	山东省腔镜外科质量控制中心胸腔镜委员会. 山东省VATS/RATS非小细胞肺癌围术期质量控制指标专家共识(2025版)[J]. 山东大学学报 (医学版), 2025, 63(12): 1-5.
[9]	李懿原,马珊,李爱华,龙飞. 超声支气管镜引导下碘-125粒子植入治疗肺癌中央区淋巴结转移[J]. 山东大学学报 (医学版), 2025, 63(12): 26-34.
[10]	刘振昆,吕纪玲,徐伟伟,马力天,张才擎. BALF tNGS检测及培养对NSCLC合并IPFD的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(11): 36-45.
[11]	山东省医学会乳腺疾病多学科联合委员会. 乳腺癌多学科协作诊疗山东共识(2024年版)[J]. 山东大学学报 (医学版), 2025, 63(1): 10-16.
[12]	张荣雨,赵文,李洪欣,杨闯,王健,韩春燕,李际盛. 奥西替尼联合化疗一线治疗EGFR-RAD51融合突变转移性肺腺癌1例[J]. 山东大学学报 (医学版), 2024, 62(5): 116-120.
[13]	华裔骨科学会骨科康复专业委员会. 全膝关节置换术后膝关节功能加速康复专家共识[J]. 山东大学学报 (医学版), 2024, 62(10): 48-61.
[14]	王亚楠,梁传杰,贾梦琪,苑辉卿. 二硫键异构酶TMX1促进肺癌化疗耐药[J]. 山东大学学报 (医学版), 2023, 61(8): 31-39.
[15]	王蕾,向淇,刘学伍. 伴系统性硬化症、类风湿关节炎的副肿瘤神经综合征1例[J]. 山东大学学报 (医学版), 2023, 61(7): 118-120.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed